William Todd Penberthy, Ph. D.
+1 (689) 247-0254 • WTPENBER@GMAIL.COM • WWW.CMESCRIBE.COM
Winter Park, Florida, USA
With a PhD in Biochemistry, I specialize in medical and scientific writing and communications for the
biomedical and pharmaceutical industries.
My scientific experience has been invaluable to my current career, enabling me to gain an understanding of various
therapeutic areas and effectively communicate CME grants, biomedical manuscripts, course design, abstracts, slide decks, and more.
Therapeutic areas include:
Neurology (multiple sclerosis, other neurodegenerative diseases, epilepsy)
2012 to Current: Principal writer CMEScribe LLC
Jan 2010-Oct 2012: Research Professor, University of Central Florida
Dec 2004-Dec 2009: Research Professor, University of Cincinnati
2000-2004: Post-doctoral fellow, UCLA
1999-2000: Post-doctoral fellow, Tufts New England Medical
Ph. D., Biochemistry, University of Tennessee, Memphis, TN
B.S., Biology, University of Central Florida, Orlando, FL
CME needs Assessments: all types of breast cancer (multiple funded), desmoid tumors (funded), multiple sclerosis (funded), SCLC (funded), HNCC, cervical cancer,
heart failure, chronic kidney disease, non-invasive prenatal testing with next generation sequencing, IgA nephropathy, idiopathic hypersomnia, Huntington’s disease, diabetes, systemic lupus
erythematosus, pediatric multiple sclerosis, schizophrenia, insomnia disorders, generalized tonic-clinic seizures, cystic fibrosis, & more
Slide decks, course design, course handouts, KoL identification/interaction
Peer-reviewed biomedical manuscripts, reviews, pharmacist guidelines, and meta-analysis:
Clinical trial studies
Basic science (animal disease models & toxicology)
Meta-analysis with statistics
Evidence based health technology assessments of emerging technologies
Published or submitted: JACC: Cardiovascular Interventions, Nature Immunology, JAMA, BMJ Open, Epilepsia, Journal
of Managed Care Specialty Pharmacy, Clinical Nutrition, Antimicrobial Agents and Chemotherapy, Biomaterials, Nanomedicine, Current Pharmaceutical Design, Current Drug Metabolism, J.
of Inherited Metabolic Diseases, EPMA J., Nutritional Metabolism, and more
Conference abstracts: > 70
News pieces with an interview with scientists just published in in Science and Nature family
of journals especially Science Translational Medicine: > 90
Systematic review with meta-analysis just published in the Journal of Lasers in Medical Sciences, 2022; Another
meta-analysis on topic has been completed. The accepted paper identified 21 RCTs meeting inclusion criteria for involving 1064nm wavelength high-powered (>1.0W) lasers used in
photobiomodulation and analysis was performed using Cohen’s d effect size calculations as a means of quantifying efficacy for these devices.
Book chapters in dermatology and nutrition: 5
Medical technology directory reports: Comprehensive reviews focused on cutting edge medical technologies for practice,
budgetary and policy decisions. Subscription only (see https://www.hayesinc.com/hayes/publications/medical-technology-directory/).
Scientific Advisor for Aspen Laser Systems, 2021- 2023 published meta-analysis
& case study using high-powered 30-watt 810nm laser photobiomodulation to effectively reverse prosopagnosia and eliminate seizures in a patient (published 2022).
White papers focused on high-throughput instrumentation platform assays towards optimal, accurate, and most reliable measures
of HbA1c and androstenedione.
Present Knowledge in Nutrition, Niacin and Biotin, 10th and 11th eds.; 2020 & 2012
Biochemical, Physiological, and Molecular Aspects of Human Nutrition, Niacin, Riboflavin, and Thiamin, 3rd and 4th eds.; 2019 &
Invited presentations: Mayo Clinic, Cleveland Clinic, panel participant (PARP1 inhibitors for
SELECT PUBLICATIONS ≤4 YEARS (more upon request)
Hedaya R, Lubar J. Reversal of Acquired Prosopagnosia Using Quantitative Electroencephalography-Guided Laser
Therapy. Photobiomodul Photomed Laser Surg 2022.
Penberthy, W. Todd and Charles Vorwaller. (2022) Utilization of the 1064 nm Wavelength in
Photobiomodulation: A Systematic Review and Meta-Analysis. Journal of Lasers in Medical
Vucic S, Kiernan MC, Menon P, Huynh W, Rynders A, Ho KS, et al. Study protocol of RESCUE-ALS: A Phase 2, randomized,
double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease
progression. BMJ Open 2021;11:e041479.
Submissions: JAMA, Epilepsia, Journal of Managed Care Specialty Pharmacy, Clinical Nutrition, Antimicrobial Agents and Chemotherapy,
Biomaterials, BMJ Open, and Nanomedicine, (2020-2022)
Penberthy, W. Todd and James B. Kirkland. Niacin (2020) in Present Knowledge in Nutrition. 11th ed.,
Elsevier, St. Louis, Mo. Edited by Diane Birt and Allison Worden.
Penberthy, W. Todd, Mahrou Sadri and Janos Zempleni. Biotin (2020) in Present Knowledge in Nutrition. 11th ed., Elsevier, St. Louis, Mo. Edited by Diane Birt and Allison Worden.
Penberthy, W. Todd. Niacin, Riboflavin, and Thiamine (2019) in Biochemical, Physiological, and Molecular Aspects of Human Nutrition.
4th ed., Elsevier, St. Louis, Mo. Edited by Marie A. Caudill and Martha H. Stipanuk.
• Penberthy, W.
Todd (2009). Nicotinic Acid-Mediated Activation of Both Membrane and Nuclear Receptors Towards Therapeutic Glucocorticoid Mimetics for Potential Treatment of Multiple Sclerosis; PPAR Research
• Penberthy, W. Todd
(guest executive editor) Current Pharmaceutical Design, 2009. Developed theme, coordinated authors / reviewers, and provided oversight to completion. Theme: NAD Biology in Disease.
• Penberthy, W. Todd
& Tsunoda, I. (2009). The Importance of NAD in Multiple Sclerosis. Current Pharmaceutical Design. 2009; 15(1): 64-99.
• Penberthy, W. Todd (2009).
Nicotinamide Biology and Disease. Current Pharmaceutical Design;15(1): 1-2.
•. Jones KS, Alimov AP, Rilo
HL, Jandacek RJ, Woollett LA, Penberthy WT. A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity
drug development. Nutr Metab (Lond) 2008;5:23.
•. Penberthy WT. Pharmacological
targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab 2007;8:245–66.
• Traver, David, Barry H. Paw,
Kenneth D. Poss, W. Todd Penberthy, Shuo Lin, and Leonard I. Zon (2003). Transplantation and in vivo Imaging of Multi-lineage Engraftment in Zebrafish Bloodless Mutants. Nature Immunology.